Evaluation of hemaPEN<sup>®</sup> sampling device for measurement of cocaine and metabolites in capillary blood by LC-MS/MS
Smidt et al.
The finding, in our words
The hemaPEN device demonstrated linear measurement of cocaine and metabolites in capillary blood with acceptable precision and accuracy, and analytes remained stable for seven days within the device. While haematocrit affected accuracy, it stayed within acceptable limits, suggesting the device could improve decentralised toxicology screening compared with conventional dried blood spot collection.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
Volumetric microsampling can enable patient-centred therapeutic drug monitoring with high patient preference and acceptable method validation for many drugs, but conversion from capillary to plasma and agreement with venous sampling varies by analyte and requires careful validation.
A validated two-step LC-MS/MS protocol can identify 91 prohibited doping agents from a single dried blood spot collected on either cellulose cards or volumetric absorptive microsampling devices. This demonstrates robust multi-analyte screening from capillary blood, supporting decentralised anti-doping programmes where venous sampling is impractical.